Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Deloitte
McKinsey
Boehringer Ingelheim
Farmers Insurance
Medtronic

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,010,585

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,010,585
Title:Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
Abstract: Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-.alpha. activity or expression; decreasing NF-.kappa.B expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity.
Inventor(s): Stankovic; Konstantina (Boston, MA), Dilwali; Sonam (Dallas, TX)
Assignee: Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:14/741,332
Patent Claims:see list of patent claims

Details for Patent 10,010,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Accenture
Federal Trade Commission
Cipla
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.